Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously optimistic about the company’s promising cancer, immunology and genetic medicines pipeline.